| # | Title | Journal | Year | Citations |
|---|
| 1 | Association analysis identifies 65 new breast cancer risk loci | Nature | 2017 | 1,099 |
| 2 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes | American Journal of Human Genetics | 2019 | 711 |
| 3 | Prognostic Value of Mature MicroRNA-21 and MicroRNA-205 Overexpression in Non–Small Cell Lung Cancer by Quantitative Real-Time RT-PCR | Clinical Chemistry | 2008 | 415 |
| 4 | Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial | Lancet Oncology, The | 2015 | 389 |
| 5 | Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type | Nature Genetics | 2014 | 383 |
| 6 | Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer | Nature Genetics | 2017 | 289 |
| 7 | Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer | British Journal of Cancer | 2009 | 283 |
| 8 | Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples | Journal of Immunological Methods | 2012 | 185 |
| 9 | A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer | Nature Genetics | 2018 | 184 |
| 10 | Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials | Lancet Oncology, The | 2020 | 152 |
| 11 | Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study | Annals of Oncology | 2012 | 133 |
| 12 | Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes | Nature Genetics | 2020 | 120 |
| 13 | A Circulating Subpopulation of Monocytic Myeloid-Derived Suppressor Cells as an Independent Prognostic/Predictive Factor in Untreated Non-Small Lung Cancer Patients | Journal of Immunology Research | 2014 | 106 |
| 14 | The promise of immunotherapy in head and neck squamous cell carcinoma | Annals of Oncology | 2016 | 95 |
| 15 | Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer | British Journal of Cancer | 2009 | 94 |
| 16 | The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status | Current Colorectal Cancer Reports | 2013 | 94 |
| 17 | Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer | Nature Communications | 2019 | 90 |
| 18 | The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type | Gynecologic Oncology | 2016 | 85 |
| 19 | Cancer therapy and cardiovascular risk: focus on bevacizumab | Cancer Management and Research | 2015 | 84 |
| 20 | Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer | Cancer | 2012 | 83 |
| 21 | Phosphorylation of FAK, PI-3K, and Impaired Actin Organization in CK-positive Micrometastatic Breast Cancer Cells | Molecular Medicine | 2007 | 80 |
| 22 | Detection of Mammaglobin A-mRNA-positive circulating tumor cells in peripheral blood of patients with operable breast cancer with nested RT-PCR | Clinical Biochemistry | 2006 | 79 |
| 23 | Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer | British Journal of Cancer | 2014 | 68 |
| 24 | SOX17 promoter methylation in plasma circulating tumor DNA of patients with non-small cell lung cancer | Clinical Chemistry and Laboratory Medicine | 2016 | 66 |
| 25 | Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer | Journal of Clinical Oncology | 2021 | 63 |
| 26 | Functional microRNA high throughput screening reveals miR-9 as a central regulator of liver oncogenesis by affecting the PPARA-CDH1 pathway | BMC Cancer | 2015 | 58 |
| 27 | Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma | JAMA Oncology | 2018 | 53 |
| 28 | Genome-wide association study of germline variants and breast cancer-specific mortality | British Journal of Cancer | 2019 | 52 |
| 29 | A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial | British Journal of Cancer | 2012 | 51 |
| 30 | Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes | JAMA Oncology | 2022 | 51 |
| 31 | Imatinib inhibits colorectal cancer cell growth and suppresses stromal‐induced growth stimulation, MT1‐MMP expression and pro‐MMP2 activation | International Journal of Cancer | 2007 | 49 |
| 32 | Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer | PLoS ONE | 2015 | 49 |
| 33 | Circulating cancer cells | Annals of Oncology | 2010 | 48 |
| 34 | Docetaxel in the treatment of advanced non-small-cell lung cancer | Expert Review of Anticancer Therapy | 2008 | 47 |
| 35 | Candidate DNA repair susceptibility genes identified by exome sequencing in high-risk pancreatic cancer | Cancer Letters | 2016 | 47 |
| 36 | Hypofractionated accelerated CT-guided interstitial 192Ir-HDR-Brachytherapy as re-irradiation in inoperable recurrent cervical lymphadenopathy from head and neck cancer | Radiotherapy and Oncology | 2011 | 45 |
| 37 | Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study | Annals of Oncology | 2012 | 45 |
| 38 | Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials | Breast Cancer Research and Treatment | 2012 | 41 |
| 39 | Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk | American Journal of Human Genetics | 2020 | 39 |
| 40 | Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer | Breast Cancer Research and Treatment | 2018 | 37 |
| 41 | Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer | British Journal of Cancer | 2013 | 32 |
| 42 | Transcriptome‐wide association study of breast cancer risk by estrogen‐receptor status | Genetic Epidemiology | 2020 | 32 |
| 43 | ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program | Lung Cancer | 2003 | 31 |
| 44 | Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer | Annals of Oncology | 2010 | 30 |
| 45 | A network analysis to identify mediators of germline-driven differences in breast cancer prognosis | Nature Communications | 2020 | 30 |
| 46 | The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer? | Annals of Oncology | 2018 | 29 |
| 47 | Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients | International Journal of Radiation Oncology Biology Physics | 2002 | 28 |
| 48 | Assessment of highly angiogenic and disseminated in the peripheral blood disease in breast cancer patients predicts for resistance to adjuvant chemotherapy and early relapse | International Journal of Cancer | 2004 | 28 |
| 49 | The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer | Npj Breast Cancer | 2019 | 28 |
| 50 | A new prognostic and predictive tool for shared decision making in stage III colon cancer | European Journal of Cancer | 2020 | 27 |
